Novo Holdings Announces Sale of KabaFusion

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Novo Holdings, a leading healthcare investment firm, announced that it has signed a definitive agreement to successfully exit its investment in KabaFusion (the "Company"). The transaction is subject to customary closing conditions.

Founded in 2010, KabaFusion is a leading U.S. provider of essential chronic and acute infusion therapies, serving patients in 45 states through its nationwide network of home infusion pharmacies, ambulatory infusion sites, and home health agencies.

Since partnering with Novo Holdings in November 2022, KabaFusion has meaningfully expanded its geographic footprint, enhanced its ambulatory infusion capabilities, and broadened its therapeutic offerings, all while maintaining the highest levels of clinical quality and the Company's patient-first approach to care delivery.

Jonathan Levy, Senior Partner at Novo Holdings, said: "When we first invested in KabaFusion, we were impressed with their clinical leadership and patient-first approach. During our partnership, the Company has expanded its national presence and nearly doubled in size. We commend Founder and CEO Dr. Sohail Masood and the entire KabaFusion management team for their extraordinary work in executing the Company's value creation plan and delivering such impressive growth, with patients at the center of everything they do."

Abhijeet Lele, Senior Partner and Head of U.S. Principal ...